

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early



Angela Colbers, Stein Schalkwijk, Deborah Konopnicki, David Hawkins, Carmen Hidalgo Tenorio, José Moltó, Graham Taylor, Katharina Weizsäcker, Marchina van der Ende, David Burger, on behalf of the PANNA network

panna

- A European clinical pharmacology network to investigate the pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women
- Pregnancy may induce changes in PK of ARVs
- Possibly sub-therapeutic levels in pregnancy as a result

Outline PANNA study protocol

General study protocol, not specified per drug, 17 ARVs



PK curve 3rd trimester
Appr wk 33 gestational age



PK curve postpartum
at least 2 weeks after
delivery

How does pregnancy affect pharmacokinetics?

gastric pH



gastric emptying and
intestinal motility



Total body water



Plasma volume



Total body fat



Albumin conc.



CYP3A4 activity



CYP2D6 activity




CYP2C19 activity



GFR



Physiological explanation



Physiological explanation

Progesterone and estradiol cause

Inhibition of enzymes

Induction of enzymes

Induction of transporters – P-gp

Both AUC and C_{\max} can be affected

Research question

Post-partum curve is used as the control curve:
normal, non-pregnant situation



Is this a valid assumption?

When should an increased dose in
pregnancy be reduced?




PK curve
at least 2 weeks
after delivery

Methods

Compounds for which lower exposure in pregnancy was observed

AUC GMR (90% CI) third trimester/postpartum



Methods

Normalise over different agents

Postpartum AUC and C_{\max} values were compared to accepted non-pregnant population AUC and C_{\max} for the specific agent

Ratio postpartum / population mean:

$$\frac{\text{Individual postpartum AUC}}{\text{Population AUC for that compound/regimen}}$$

Methods

The time-point of the postpartum curve was grouped per week.
>8 weeks postpartum pooled


Kruskal Wallis test with weeks postpartum as grouping variable was used for statistical analysis.

Results

157 postpartum curves, from 67 unique patients


Characteristics	Median (range)
Age at delivery (years)	32 (19-45)
Race	
Black	60%
White	39%
Other	1%
Weight at postpartum (kg)	71 (43-126)
Weight at 3 rd trimester (kg)	76 (48-139)

Results



Results


AUC relative to reference



Kruskall Wallis
 $p = 0.337$

Results

C_{\max} relative to reference



Kruskall Wallis
 $p = 0.227$

Conclusion

- No time effect was observed for postpartum curves taken at least 3 weeks post delivery
- Postpartum curves from at least 3 weeks post delivery were comparable to non-pregnant population means
- Dose reductions (after dose increase in pregnancy) should be considered from > 2 weeks post delivery onwards

THANKS TO

Participants in PANNA study

Investigators of the PANNA study

Financial support

- For PANNA: NEAT/PENTA; Merck; BMS; Janssen, ViiVHealthcare

Website: **panna**
www.pannastudy.com